Month: June 2021

                                                                                                       Charenton-le-Pont, 30th June 2021 DESCRIPTION OF THE SHARE BUYBACK PROGRAM AUTHORIZED BY THE ORDINARY GENERAL MEETING OF SHAREHOLDERS OF JUNE 30, 2021 In accordance with the provisions of Articles 241-2 et seq. of the General Regulations of the French Financial Markets Authority (Autorité des Marchés Financiers) and European Regulation No. 596/2014 of April 16, 2014, the purpose of this description is to describe the purposes and terms of the share buyback program by Marie Brizard Wine & Spirits under the authorization granted by the 16th resolution of the Combined General Meeting of Shareholders on June 30, 2021. Breakdown of shares held by the Company by objective As of June 24, 2021, the Company holds 127,888 treasury shares,...

Charenton-le-Pont, June 30th, 2021 Vote results on the Ordinary General Meeting resolutions of June 30th, 2021 Marie Brizard Wine & Spirits (Euronext: MBWS) today announces that the Ordinary General Meeting of the Company’s shareholders was held on June 30th, 2021 at 9:30 am at the Company’s headquarters, chaired by Mr George Graux, Chairman of the Board Directors. In accordance with the provisions of the Order n°2020-321 of March 25th 2020 issued in the context of the Covid-19 health crisis and extended by Decree n°2021-255 of March 9th 2021, it was held exceptionally behind closed doors, without the physical presence of the shareholders and of the persons entitled to attend. However, shareholders were able to vote by proxy or cast their votes remotely, by mail or via the VOTACCESS platform upstream meeting. 257 shareholders were...

CONSHOHOCKEN, Pa., June 30, 2021 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today achievement of the planned target enrollment in the Phase 3 clinical trial, MAESTRO-NASH. Serial liver biopsy and safety data from patients enrolled in MAESTRO-NASH coupled with safety data from MAESTRO-NAFLD-1, an additional large Phase 3 study, are expected to support the planned Subpart H (Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses) submission to the US Food and Drug Administration (FDA). Madrigal will continue to enroll additional patients beyond those required for accelerated approval to provide for the clinical outcomes portion of the MAESTRO-NASH Phase 3 clinical trial of resmetirom. Becky Taub, M.D., Chief Medical Officer and President of Research & Development of Madrigal,...

NEW YORK and LONDON, June 30, 2021 (GLOBE NEWSWIRE) — Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces an interview with the Chairman of its’ Scientific Advisory Board and Professor of Neurology at Harvard Medical School, Dr Howard Weiner is to air on Bloomberg Markets with Matt Miller and Amanda Lang today at 1.50pm ET/6.50pm BST. About Tiziana Life Sciences Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In addition to Milciclib (a CDK inhibitor being developed in oncology), the Company is also developing Foralumab in COVID-19, multiple sclerosis, and Crohn’s...

In the context of the Covid-19 pandemic and in light of the applicable restrictions, the Ordinary General Meeting of Solutions 30 was held on 30 June 2021, chaired by Gianbeppi Fortis, Chairman of the Management Board. All the resolutions proposed to the Ordinary General Meeting were adopted. In particular, the Ordinary General Meeting approved:The statutory and consolidated accounts for the financial year 2020 The appointment of PKF Audit & Conseil Luxembourg as statutory auditor The renewal of the mandates of M. Jean-Paul COTTET, Ms Caroline TISSOT, M. Paul RAGUIN and M. Francesco SERAFINI, as members of the Supervisory Board of the Company for a 4-year term.As far as the Extraordinary General Meeting is concerned, the quorum not being reached, it will therefore be reconvened to vote on the two resolutions related to the authorized...

LONDON, June 30, 2021 (GLOBE NEWSWIRE) — Exela Technologies, Inc. (“Exela”) (NASDAQ: XELA) today announced that the Digital Mailroom (DMR) platform is live and available for online signups for small and medium businesses (SMBs) in the UK. With the remote working trend getting wider acceptance, a greater shift is seen in the operations of SMBs where more people are opting to work from home for better flexibility. Exela DMR will now cater to this growing customer base across Europe, starting with the UK. The DMR platform is already available for Exela’s enterprise customers across Europe. Small and mid-sized businesses, start-ups, and individual professional in the UK can now signup for the Exela DMR, allowing them to get a virtual office address and receive their incoming mail as digitised documents accessible via the DMR portal....

HRC WORLD PLC NASDAQ FIRST NORTH, COPENHAGENTICKER: HRCISIN: GB00BZ3CDY20 30 JUNE 2021 Unaudited Preliminary Consolidated Results for year ended 31 March 2021 The Board of Directors of HRC World Plc (the “Company”), are pleased to announce that the Company has approved its Unaudited Preliminary Consolidated Results for the financial year ended 31 March 2021. The Company recorded a revenue US$ 368,000 for the period as opposed to having no revenue in the corresponding period last year. Operational overheads resulted in a profit before tax of US$ 13,000 from continuing operations compared to a loss from continuing operation of US$ 690,000 for the year ended 31 March 2020 During the past year, the Company has taken time to study and understand the effects of the COVID pandemic on food and beverage businesses especially on restaurants, in...